Brief: Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
05/02/2025 13:38
Feb 5 (Reuters) - VistaGen Therapeutics Inc VTGN.O :
* VISTAGEN RECEIVES U.S. PATENT FOR AV-101 TO TREAT
NEUROPATHIC
PAIN
* VISTAGEN THERAPEUTICS-PLANS TO SEEK POTENTIAL STRATEGIC
COLLABORATIONS TO FURTHER ADVANCE POTENTIAL CLINICAL
DEVELOPMENT, COMMERCIALIZATION OF AV-101
* VISTAGEN THERAPEUTICS INC - PATENT WILL NOT EXPIRE UNTIL
AT
LEAST 2034
Source text: ID:nBw3rMzwHa
Further company coverage: VTGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors